S-14671

S-14671 is a drug that was developed by the pharmaceutical company Servier. It is classified as an antidepressant, specifically a serotonin-norepinephrine reuptake inhibitor (SNRI).

Pharmacology

S-14671 works by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters in the brain. This increases the amount of these neurotransmitters available in the brain, which can help to alleviate symptoms of depression.

Development and Clinical Trials

S-14671 was developed by Servier Laboratories, a French pharmaceutical company. It underwent clinical trials to assess its safety and efficacy as a treatment for depression. However, the results of these trials have not been publicly disclosed, and it is unclear whether the drug is currently being marketed.

Side Effects

As with all drugs, S-14671 has the potential to cause side effects. These can vary widely between individuals and may include nausea, headache, insomnia, and dizziness. It is important for patients to discuss any potential side effects with their healthcare provider before starting treatment.

See Also

• Antidepressant
• Serotonin-norepinephrine reuptake inhibitor
• Clinical trial
• Side effect

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

S-14671

• 
  S-14671 structure
• 
  S-14671 3D spacefill